On Tuesday, July 23, Knobbe Martens hosted a live webinar event covering "Preparing for Biosimilars: Key Points for Participating in the U.S. Regulatory Framework." Partners Eli Loots, Carol Pitzel Cruz, and Sheila Swaroop participated as panelists, along with Michael Fuller as the moderator.
- Excerpt from Presentation: Biologics Overview:
Biologics Price Competition and Innovation Act (“BPCIA”) -
• Signed into law March 23, 2010, as part of the Patient Protection and Affordable Care Act of 2009; amends §351 of Public Health Services Act.
• Codified at 42 U.S.C.§262.
• Creates an abbreviated approval pathway for ‘biological products’ that are demonstrated to be highly similar (i.e., biosimilar) to or interchangeable with an FDA-licensed reference biological product.
Please see full presentation below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.
Topics: Affordable Care Act, America Invents Act, Biosimilars, BPCIA, Ex Partes Reexamination, FDA, Healthcare, Patent Reform, Patents
Published In: Intellectual Property Updates, Science, Computers & Technology Updates
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Knobbe Martens Olson & Bear LLP | Attorney Advertising